NervGen Pharma
NGEN
62 hedge funds and large institutions have $24.9M invested in NervGen Pharma in 2026 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 20 increasing their positions, 7 reducing their positions, and 3 closing their positions.
3,008% more call options, than puts
Call options by funds: $777K | Put options by funds: $25K
567% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 3
287% more capital invested
Capital invested by funds: $6.42M → $24.9M (+$18.4M)
186% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 7
38% more funds holding
Funds holding: 45 → 62 (+17)
12.77% more ownership
Funds ownership: 2.1% → 14.87% (+13%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Empery Asset Management
New York
|
+$12.4M |
| 2 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$3.75M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$3.26M |
| 4 |
GCM
Ghisallo Capital Management
Boston,
Massachusetts
|
+$3.1M |
| 5 |
AC
Armistice Capital
New York
|
+$2.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VFIC
Valley Forge Investment Consultants
Audubon,
Pennsylvania
|
-$210K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$44.9K |
| 3 |
IWC
Integrated Wealth Concepts
Waltham,
Massachusetts
|
-$39.1K |
| 4 |
PFGIA
Patriot Financial Group Insurance Agency
Westborough,
Massachusetts
|
-$26.4K |
| 5 |
MCM
MAI Capital Management
Independence,
Ohio
|
-$2.64K |
NGEN Hedge Fund Activity: Q2 2026 in Review
62 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in NervGen Pharma (NGEN) for Q2 2026, worth a combined $24.9M — up 287% from $6.42M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new NGEN positions and 3 closed out — a net gain of 17 holders — while 20 added to existing stakes and 7 trimmed.
The largest buyer was Empery Asset Management, opening a new position worth an estimated $12.4M. The largest seller was Valley Forge Investment Consultants, cutting an estimated $210K.
- 62 institutional investors held NervGen Pharma (NGEN) as of Q2 2026, up from 45 in Q1 2026.
- Funds reported $24.9M of NervGen Pharma stock for Q2 2026, up 287% quarter-over-quarter.
- 20 funds opened new NervGen Pharma positions in Q2 2026 and 3 closed out, a net change of +17 holders.
- The largest NervGen Pharma buyer in Q2 2026 was Empery Asset Management, an estimated $12.4M added.
- The largest NervGen Pharma seller in Q2 2026 was Valley Forge Investment Consultants, an estimated $210K sold.
Based on aggregated 13F filings for Q2 2026.